A CRA expert was retained in an antitrust matter involving patent settlement agreements between branded and generic pharmaceutical manufacturers that involved so-called ‘reverse payments’. Plaintiffs alleged that the agreements involved a conspiracy to fix prices and allocate markets, and that this conspiracy involved an exclusionary scheme to maintain a monopoly. CRA’s expert determined that generic versions of the drug would not likely have entered earlier absent the settlement agreements, the relevant market included competing branded products, and the agreements were not anticompetitive.
Comments on the effect of algorithms and artificial intelligence on the likelihood of coordinated effects as described in Guideline 3 of the draft Merger Guidelines
In this note, we discuss how the Antitrust Division of the Department of Justice and the Federal Trade Commission (collectively, the Agencies) view the effect...